Maintenance of CD4+ T-cell memory and HIV persistence: Keeping memory, keeping HIV

Current Opinion in HIV and AIDS

Volumn 6, Issue 1, 2011, Pages 30-36

  Chomonta, Nicolas ^a   DaFonsecaa, Sandrina ^a   Vandergeetena, Claire ^a   Ancuta, Petronela ^b,c   Sékaly, Rafick Pierre ^a,b,c  

^a VGTI FL   (United States)

^b UNIVERSITY OF MONTREAL   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Cell survival; Highly active antiretroviral therapy; HIV; Interleukin 7; Viral reservoirs

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CYTOKINE;

ARTICLE; CD4+ T LYMPHOCYTE; CELL SURVIVAL; CYTOKINE PRODUCTION; EFFECTOR CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MEMORY T LYMPHOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; PATHOGENICITY; REVIEW; VIROLOGY; VIRUS LATENCY;

CD4-POSITIVE T-LYMPHOCYTES; HIV; HIV INFECTIONS; HUMANS; IMMUNOLOGIC MEMORY; VIRUS LATENCY;

EID: 79954436446     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3283413775     Document Type: Article

References (72)

1. Garrigue I, Pellegrin I, Hoen B, et al. Cell-associated HIV-1-DNA quantitation after highly active antiretroviral therapy-treated primary infection in patients with persistently undetectable plasma HIV-1 RNA. AIDS 2000; 14:2851-2855. (Pubitemid 32042748)
2. Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A 1997; 94:13193-13197. (Pubitemid 27518498)
3. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278: 1291-1295. (Pubitemid 27495741)
4. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278:1295-1300. (Pubitemid 27495742)
5. Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5:512-517. (Pubitemid 29220209)
6. Siliciano JD, Kajdas J, Finzi D, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003; 9:727-728. (Pubitemid 36749221)
7. Hammarlund E, Lewis MW, Hansen SG, et al. Duration of antiviral immunity after smallpox vaccination. Nat Med 2003; 9:1131-1137. (Pubitemid 37173696)
8. Combadiere B, Boissonnas A, Carcelain G, et al. Distinct time effects of vaccination on long-term proliferative and IFN-gamma-producing T cell memory to smallpox in humans. J Exp Med 2004; 199:1585-1593. (Pubitemid 38780413)
9. Amara RR, Nigam P, Sharma S, et al. Long-lived poxvirus immunity, robust CD4 help, and better persistence of CD4 than CD8 T cells. J Virol 2004; 78:3811-3816. (Pubitemid 38437186)
10. Douek DC, Brenchley JM, Betts MR, et al. HIV preferentially infects HIVspecific CD4+ T cells. Nature 2002; 417:95-98. (Pubitemid 34498823)
11. Zaunders JJ, Dyer WB, Wang B, et al. Identification of circulating antigenspecific CD4+ T lymphocytes with a CCR5+, cytotoxic phenotype in an HIV-1 long-termnonprogressor and inCMV infection. Blood 2004; 103:2238-2247. (Pubitemid 38326243)
12. Casazza JP, Brenchley JM, Hill BJ, et al. Autocrine production of betachemokines protects CMV-specific CD4 T cells from HIV infection. PLoS Pathog 2009; 5:e1000646.
13. Koelsch KK, Liu L, Haubrich R, et al. Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro. J Infect Dis 2008; 197:411-419. (Pubitemid 351263423)
14. Chomont N, El-Far M, Ancuta P, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009; 15:893-900.
15. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004; 22:745-763. (Pubitemid 38680440)
16. Sallusto F, Lenig D, Forster R, et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401: 708-712.
17. Riou C, Yassine-Diab B, Van grevenynghe J, et al. Convergence of TCR and cytokine signaling leads to FOXO3a phosphorylation and drives the survival of CD4+ central memory T cells. J Exp Med 2007; 204:79-91. (Pubitemid 46148759)
18. Geginat J, Sallusto F, Lanzavecchia A. Cytokine-driven proliferation and differentiation of human naive, central memory and effector memory CD4+ T cells. Pathol Biol (Paris) 2003; 51:64-66. (Pubitemid 36427572)
19. Deeks SG, Walker BD. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 2007; 27:406-416. (Pubitemid 47418678)
20. van Grevenynghe J, Procopio FA, He Z, et al. Transcription factor FOXO3a controls the persistence of memory CD4+ T cells during HIV infection. Nat Med 2008; 14:266-274. (Pubitemid 351347916)
21. Chang JT, Palanivel VR, Kinjyo I, et al. Asymmetric T lymphocyte division in the initiation of adaptive immune responses. Science 2007; 315:1687-1691. (Pubitemid 46515618)
22. Ahmed R, Bevan MJ, Reiner SL, Fearon DT. The precursors of memory: models and controversies. Nat Rev Immunol 2009; 9:662-668.
23. Williams MA, Ravkov EV, Bevan MJ. Rapid culling of the CD4+ T cell repertoire in the transition from effector to memory. Immunity 2008; 28:533-545.
24. Harrington LE, Janowski KM, Oliver JR, et al. Memory CD4 T cells emerge from effector T-cell progenitors. Nature 2008; 452:356-360. (Pubitemid 351430787)
25. Lohning M, Hegazy AN, Pinschewer DD, et al. Long-lived virus-reactive memory T cells generated from purified cytokine-secreting T helper type 1 and type 2 effectors. J Exp Med 2008; 205:53-61. (Pubitemid 351185715)
26. + T cell effectors can become memory cells with high efficiency and without further division. Nat Immunol 2001; 2:705-710. (Pubitemid 32747159)
27. Halwani R, Doroudchi M, Yassine-Diab B, et al. Generation and maintenance of human memory cells during viral infection. Springer Semin Immunopathol 2006; 28:197-208. (Pubitemid 44764276)
28. Champagne P, Dumont AR, Sekaly RP. Learning to remember: generation and maintenance of T-cell memory. DNA Cell Biol 2001; 20:745-760.
29. Seddon B, Tomlinson P, Zamoyska R. Interleukin 7 and T cell receptor signals regulate homeostasis of CD4 memory cells. Nat Immunol 2003; 4:680-686. (Pubitemid 36874445)
30. Kassiotis G, Garcia S, Simpson E, Stockinger B. Impairment of immunological memory in the absence of MHC despite survival of memory T cells. Nat Immunol 2002; 3:244-250. (Pubitemid 34213425)
31. De Riva A, Bourgeois C, Kassiotis G, Stockinger B. Noncognate interaction with MHC class II molecules is essential for maintenance of T cell metabolism to establish optimal memory CD4 T cell function. J Immunol 2007; 178:5488-5495. (Pubitemid 46674343)
32. Bushar ND, Corbo E, Schmidt M, et al. Ablation of SLP-76 signaling after T cell priming generates memory CD4 T cells impaired in steady-state and cytokine-driven homeostasis. Proc Natl Acad Sci U S A 2010; 107:827-831.
33. Soroosh P, Ine S, Sugamura K, Ishii N. OX40-OX40 ligand interaction through T cell-T cell contact contributes to CD4 T cell longevity. J Immunol 2006; 176:5975-5987.
34. Leignadier J, Hardy MP, Cloutier M, et al. Memory T-lymphocyte survival does not require T-cell receptor expression. Proc Natl Acad Sci U S A 2008; 105:20440-20445.
35. van Leeuwen EM, Sprent J, Surh CD. Generation and maintenance of memory CD4+ T cells. Curr Opin Immunol 2009; 21:167-172.
36. Kondrack RM, Harbertson J, Tan JT, et al. Interleukin 7 regulates the survival and generation of memory CD4 cells. J Exp Med 2003; 198:1797-1806. (Pubitemid 38032113)
37. Lenz DC, Kurz SK, Lemmens E, et al. IL-7 regulates basal homeostatic proliferation of antiviral CD4+T cell memory. Proc Natl Acad Sci U S A 2004; 101:9357-9362. (Pubitemid 38812880)
38. Purton JF, Tan JT, Rubinstein MP, et al. Antiviral CD4+ memory T cells are IL-15 dependent. J Exp Med 2007; 204:951-961. (Pubitemid 46631622)
39. Chetoui N, Boisvert M, Gendron S, Aoudjit F. Interleukin-7 promotes the survival of human CD4 effector/memory T cells by up-regulating Bcl-2 proteins and activating the JAK/STAT signalling pathway. Immunology 2010; 130:418-426.
40. Wojciechowski S, Jordan MB, Zhu Y, et al. Bim mediates apoptosis of CD127(lo) effector T cells and limits T cell memory. Eur J Immunol 2006; 36:1694-1706. (Pubitemid 44089037)
41. Jacobs SR, Michalek RD, Rathmell JC. IL-7 is essential for homeostatic control of T cell metabolism in vivo. J Immunol 2010; 184:3461-3469.
42. Chun TW, Finzi D, Margolick J, et al. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med 1995; 1:1284-1290.
43. Demoustier A, Gubler B, Lambotte O, et al. In patients on prolonged HAART, a significant pool of HIV infected CD4 T cells are HIV-specific. AIDS 2002; 16:1749-1754.
44. Lambotte O, Chaix ML, Gubler B, et al. The lymphocyte HIV reservoir in patients on long-term HAART is a memory of virus evolution. AIDS 2004; 18:1147-1158. (Pubitemid 38738514)
45. Rong L, Perelson AS. Asymmetric division of activated latently infected cells may explain the decay kinetics of the HIV-1 latent reservoir and intermittent viral blips. Math Biosci 2009; 217:77-87.
46. Rajasuriar R, Booth D, Solomon A, et al. Biological determinants of immune reconstitution in HIV-infected patients receiving antiretroviral therapy: the role of interleukin 7 and interleukin 7 receptor alpha and microbial translocation. J Infect Dis 2010; 202:1254-1264.
47. Marchetti G, Gori A, Casabianca A, et al. Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART. AIDS 2006; 20:1727-1736. (Pubitemid 44299364)
48. Anthony KB, Yoder C, Metcalf JA, et al. Incomplete CD4 T cell recovery in HIV-1 infection after 12 months of highly active antiretroviral therapy is associated with ongoing increased CD4 T cell activation and turnover. J Acquir Immune Defic Syndr 2003; 33:125-133. (Pubitemid 36793144)
49. Catalfamo M, Di Mascio M, Hu Z, et al. HIV infection-associated immune activation occurs by two distinct pathways that differentially affect CD4 and CD8 T cells. Proc Natl Acad Sci U S A 2008; 105:19851-19856.
50. Napolitano LA, Grant RM, Deeks SG, et al. Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. Nat Med 2001; 7:73-79. (Pubitemid 32095644)
51. Camargo JF, Kulkarni H, Agan BK, et al. Responsiveness of T cells to interleukin-7 is associated with higher CD4+ T cell counts in HIV-1-positive individuals with highly active antiretroviral therapy-induced viral load suppression. J Infect Dis 2009; 199:1872-1882.
52. Benito JM, Lopez M, Lozano S, et al. Down-regulation of interleukin-7 receptor (CD127) in HIV infection is associated with T cell activation and is a main factor influencing restoration of CD4(+) cells after antiretroviral therapy. J Infect Dis 2008; 198:1466-1473.
53. Scripture-Adams DD, Brooks DG, Korin YD, Zack JA. Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype. J Virol 2002; 76:13077-13082. (Pubitemid 35386993)
54. Wang FX, Xu Y, Sullivan J, et al. IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest 2005; 115:128-137. (Pubitemid 40385513)
55. Sereti I, Dunham RM, Spritzler J, et al. IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood 2009; 113:6304-6314.
56. Levy Y, Lacabaratz C, Weiss L, et al. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest 2009; 119:997-1007.
57. Jeeninga RE, Westerhout EM, van Gerven ML, Berkhout B. HIV-1 latency in actively dividing human T cell lines. Retrovirology 2008; 5:37.
58. Bull ME, Learn GH, McElhone S, et al. Monotypic human immunodeficiency virus type 1 genotypes across the uterine cervix and in blood suggest proliferation of cells with provirus. J Virol 2009; 83:6020-6028.
59. Kim H, Perelson AS. Viral and latent reservoir persistence in HIV-1-infected patients on therapy. PLoS Comput Biol 2006; 2:e135.
60. Strain MC, Little SJ, Daar ES, et al. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis 2005; 191:1410-1418. (Pubitemid 40563351)
61. Chun TW, Justement JS, Moir S, et al. Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J Infect Dis 2007; 195:1762-1764. (Pubitemid 46870248)
62. Hocqueloux L, Prazuck T, Avettand-Fenoel V, et al. Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. AIDS 2010; 24:1598-1601.
63. Lehrman G, Hogue IB, Palmer S, et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 2005; 366:549-555. (Pubitemid 41140329)
64. Archin NM, Eron JJ, Palmer S, et al. Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS 2008; 22:1131-1135.
65. Sagot-Lerolle N, Lamine A, Chaix ML, et al. Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. AIDS 2008; 22:1125-1129.
66. Siliciano JD, Lai J, Callender M, et al. Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis 2007; 195:833-836. (Pubitemid 46363928)
67. Brenchley JM, Douek DC. HIV infection and the gastrointestinal immune system. Mucosal Immunol 2008; 1:23-30.
68. Gosselin A, Monteiro P, Chomont N, et al. Peripheral blood CCR4+CCR6+ and CXCR3+CCR6+CD4+ T cells are highly permissive to HIV-1 infection. J Immunol 2010; 184:1604-1616.
69. Arthos J, Cicala C, Martinelli E, et al. HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol 2008; 9:301-309. (Pubitemid 351267327)
70. Cicala C, Martinelli E, McNally JP, et al. The integrin {alpha}4{beta}7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc Natl Acad Sci U S A 2009; 106:20877-20882.
71. Dinoso JB, Rabi SA, Blankson JN, et al. A simian immunodeficiency virusinfected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy. J Virol 2009; 83:9247-9257.
72. Lewis MG, Norelli S, Collins M, et al. Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy. Retrovirology 2010; 7:21.